Compare EBF & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EBF | NMRA |
|---|---|---|
| Founded | 1909 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 436.2M | 424.4M |
| IPO Year | N/A | 2023 |
| Metric | EBF | NMRA |
|---|---|---|
| Price | $17.68 | $2.08 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 203.4K | ★ 1.1M |
| Earning Date | 12-19-2025 | 11-06-2025 |
| Dividend Yield | ★ 5.67% | N/A |
| EPS Growth | ★ 3.59 | N/A |
| EPS | ★ 1.63 | N/A |
| Revenue | ★ $388,344,000.00 | N/A |
| Revenue This Year | $0.96 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.72 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $16.30 | $0.61 |
| 52 Week High | $22.01 | $11.57 |
| Indicator | EBF | NMRA |
|---|---|---|
| Relative Strength Index (RSI) | 57.53 | 40.16 |
| Support Level | $16.51 | $2.13 |
| Resistance Level | $17.91 | $2.36 |
| Average True Range (ATR) | 0.32 | 0.18 |
| MACD | 0.08 | -0.05 |
| Stochastic Oscillator | 80.82 | 4.62 |
Ennis Inc is a manufacturer and supplier of print products for the wholesale trade. The company's products include advertising specialties, business forms and supplies, commercial printing, eCommerce solutions, envelopes, labels and tags, and folders and packaging. Its products include snap sets, continuous forms, laser cut sheets, tags, labels, envelopes, integrated products, jumbo rolls, and pressure-sensitive products in short, medium and long runs under the following labels: Ennis, Royal Business Forms, Block Graphics, 360 Custom LabelsSM, ColorWorx, Enfusion, among others.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.